{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-271116","form_type":"8-K","ticker":"CGON","cik":"0001991792","company_name":"CG Oncology, Inc.","filed_at":"2024-12-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.529276+00:00","generated_at":"2026-05-29T07:29:08.346120+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"CG Oncology reports 74.5% CR rate in Phase 3 BOND-003; median DOR >27 months","bullets":["74.5% (82/110) achieved complete response at any time (95% CI 65.4-82.4%).","Median duration of response not reached but exceeds 27 months; 63.5% probability of response at 12 months.","No Grade 3+ treatment-related adverse events or deaths; 97.3% completed all treatments.","Progression-free survival at 12 months: 97.3%; no progression to muscle-invasive cancer.","Cystectomy-free survival at 12 months: 90.0%; 50% of reinduced patients converted to CR."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-271116","json":"https://secwatch.observer/filing/0001193125-24-271116.json","markdown":"https://secwatch.observer/filing/0001193125-24-271116.md","text":"https://secwatch.observer/filing/0001193125-24-271116.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1991792/000119312524271116/0001193125-24-271116-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1991792/000119312524271116/d809707d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T07:29:08.346120+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}